Hyloris Signs Exclusive Distribution Agreement with AFT Pharmaceuticals for Phosphate Oral Liquid in Five International Markets

- Exclusive distribution agreement covering Australia, Canada, New Zealand, Hong Kong and Singapore
- Commercial agreement based on profit sharing
- Partnership further strengthens the longstanding collaboration between Hyloris and AFT Pharmaceuticals

Liège, Belgium – 6 November 2026 – 7.30 AM CET – Regulated Information – Inside Information – Hyloris Pharmaceuticals SA ("Hyloris") (Euronext Brussels: HYL), the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, today announces an exclusive distribution agreement with AFT Pharmaceuticals ("AFT") for its proprietary Phosphate Oral Liquid formulation (HY-088) in Australia, Canada, New Zealand, Hong Kong and Singapore.

Phosphate Oral Liquid is a ready-to-use oral formulation developed for the treatment of hypophosphatemia, a condition characterised by abnormally low phosphate levels in the blood. The product aims to address limitations of existing phosphate supplementation options by providing a standardised formulation offering accurate dosing, convenient administration and improved treatment consistency.

Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: "*We are pleased to further expand our successful partnership with AFT Pharmaceuticals. Phosphate Oral Liquid is another example of our strategy to improve established treatments by addressing practical unmet medical needs. Although phosphate supplementation is well established, existing formulations can present challenges in dosing accuracy and convenience. Our proprietary ready-to-use formulation aims to offer a simpler and more reliable alternative for patients and healthcare professionals*."

Under the agreement, AFT will obtain exclusive commercialisation rights in the licensed territories. Parties will share profits generated from commercial sales.

The agreement builds on the longstanding collaboration between Hyloris and AFT, including Maxigesic® IV and other value-added medicine programs. Hyloris has already submitted several regulatory applications for Phosphate Oral Liquid to health authorities in the European Union. The Company has already secured patent protection in several countries, with further applications pending in other jurisdictions.

About Phosphate Oral Liquid

Phosphate Oral Liquid (HY-088) is a proprietary ready-to-use oral formulation developed for the treatment of hypophosphatemia. The product is designed to provide a standardised and convenient alternative to existing phosphate preparations, potentially improving dosing accuracy, consistency and ease of administration.

About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payers. The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio including more than 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved and commercialized in the U.S.: Podofilox Gel and Tranexamic Acid RTU. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. ***Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide***. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (XBR: HYL) with about 54 people across 13 nationalities, targeting time-to-market of 7 years at an average cost of EUR 7 million per product (non-inflation adjusted).

For more information, visit www.hyloris.com and follow us on LinkedIn.

About AFT Pharmaceuticals Ltd

AFT Pharmaceuticals is a listed (NZE: AFT) and growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories. Its business model focuses on developing and in-licensing patented, branded, and generic products for commercialization. AFT has direct operations in Australia, New Zealand, Singapore, Hong Kong, South Africa, Canada, and the United Kingdom and has out-licensed products to licensees and distributors in over 120 countries worldwide. Learn more at **www.aftpharm.com**

Contacts Hyloris Pharmaceuticals:

Ann De Jaeger, CLO
legal representative of Impact WITH Empathy BV
Ann.dejaeger@hyloris.com
+32 (0)475 20 13 44 - +32 (0)4 346 02 07

Stijn Van Rompay, CEO
legal representative of SVR Management BV
stijn.vanrompay@hyloris.com
+32 (0)4 346 02 07

Christophe Maréchal, CFO
legal representative of CMM&C srl
Christophe.Marechal@hyloris.com
+32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means "high yield, lower risk", which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are "forward-looking statements." These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

This press release contains information about a product under development and is not intended as a promotional statement. The product mentioned is subject to regulatory approval and is not currently available for sale. Please consult licensed medical professionals for healthcare decisions.